Wayne Kuznar


Authored Items

Cediranib-Based Combination Therapy Extends Progression-Free Survival in Relapsed Ovarian Cancer

July 2017, Vol 7, No 7 - ASCO 2017 Highlights

Chicago, IL—Oral cediranib, an investigational vascular endothelial growth factor (VEGF) inhibitor, in combination with a poly ADP-ribose polymerase (PARP) inhibitor or with chemotherapy, shows survival benefit in women with relapsed platinum-sensitive ovarian cancer, according to data from 2 studies presented at the 2017 American Society of Clinical Oncology meeting. [ Read More ]

Identifying Correct Molecular Target Essential for Treating Non–Small-Cell Lung Cancer

June 2017, Vol 7, No 6 - NCCN 2017 Conference Highlights

Orlando, FL—Non–small-cell lung cancer (NSCLC) comprises several different subtypes, necessitating broad molecular panel testing to understand the correct diagnosis and the appropriate treatment, said Wallace Akerley, MD, Senior Director, Community Oncology Research, Huntsman Cancer Institute, University of Utah, Salt Lake City, at the 2017 National Comprehensive Cancer Network (NCCN) annual conference. [ Read More ]

Combination Therapies Dominate NCCN Guidelines for Multiple Myeloma

June 2017, Vol 7, No 6 - NCCN 2017 Conference Highlights

Orlando, FL—The ideal treatment in 2017 for patients with newly diagnosed multiple myeloma is a combination of bor­tezomib (Velcade), lenalidomide (Revlimid), and dexamethasone. Bortezomib-based maintenance therapy is particularly relevant in patients with high-risk disease and residual disease, and in the relapsed setting, triplet therapy is preferred over doublet therapy. These are among the key therapeutic points in the current National Comprehensive Cancer Network (NCCN) guideline for the management of multiple myeloma (version 3.2017), said Shaji K. Kumar, MD, Professor of Medicine, Mayo Clinic Cancer Center, Rochester, MN, at the 2017 NCCN annual conference. He discussed the use of current therapies based on the NCCN guidelines. [ Read More ]

Immunotherapy-Related Adverse Reactions: Grading of Symptoms Key to Appropriate Management

May 2017, Vol 7, No 5 - NCCN Conference Highlights

Orlando, FL—Enthusiasm for immunotherapy in the treatment of cancer must be balanced with a healthy respect for the power of T-cell activation. Autoimmunity is recognized as an effect of prolonged T-cell activation via PD-1/PD ligand 1 inhibition. Although immune-related adverse events are generally easily managed, they occasionally can be fatal and therefore should be managed without delay, said Stephanie Andrews, MS, ANP-BC, a hospitalist specializing in medical oncology at Moffitt Cancer Center, Tampa, FL, at the 2017 National Comprehensive Cancer Network (NCCN) annual conference. [ Read More ]

Anti-CD19 CAR T-Cell Therapy After Stem-Cell Transplantation Effective in Advanced Multiple Myeloma

March 2017, Vol 7, No 3 - Emerging Therapies

Anti-CD19 chimeric antigen receptor (CAR) T-cell administration after autologous stem-cell transplantation (ASCT) showed clinical activity in patients with advanced multiple myeloma, according to results of a pilot study presented at the 2016 American Society of Hematology meeting. Substantially longer progression-free survival (PFS) was seen in 2 of 10 patients who received ASCT plus CTL019 than in patients who received first-line ASCT, said Alfred L. Garfall, MD, MS, Assistant Professor of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia. [ Read More ]

CAR-Targeting CD22 an Effective Salvage Therapy in Relapsed Pediatric Acute Lymphoblastic Leukemia

March 2017, Vol 7, No 3 - Emerging Therapies

Chimeric antigen receptor (CAR)-targeting CD22 therapy induced clinical responses and a high rate of complete remission in children and young adults with relapsed or refractory acute lymphoblastic leukemia (ALL), including patients who had received anti-CD19 CAR T-cell therapy, said Terry J. Fry, MD, Hematologic Malignancies Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute (NCI), at the 2016 American Society of Hematology meeting. These findings create the opportunity for bispecific or multispecific CAR T-cell targeting. [ Read More ]

Reduced-Dose Sorafenib with Uptitration in Hepatocellular Carcinoma Is Cost-Saving Without Compromising Outcome

March 2017, Vol 7, No 3 - GI Cancers Symposium

Starting at a low dose of sorafenib (Nexavar) and titrating up to the full dose of 800 mg, rather than starting the full dose, does not adversely affect outcomes, while improving tolerability and reducing costs in the treatment of patients with hepatocellular carcinoma (HCC). This was the conclusion from a review of 4900 veterans diagnosed with HCC who were prescribed sorafenib at Veterans Administration (VA) hospitals. [ Read More ]

Nivolumab a New Treatment Option for Patients with Advanced Gastric Cancer

March 2017, Vol 7, No 3 - GI Cancers Symposium

Nivolumab (Opdivo) as salvage treatment significantly reduced the risk for death after second-line or later chemotherapy in patients with advanced gastric or gastroesophageal junction cancer. In a double-blind, randomized phase 3 trial, the median overall survival was improved by 37% in patients assigned to nivolumab versus placebo after previous treatment with at least 2 regimens, reported Yoon-Koo Kang, MD, PhD, Department of Oncology, Asan Medical Center, Seoul, South Korea, at the 2017 Gastrointestinal Cancers Symposium. [ Read More ]

Cisplatin Added to Standard Regimen Leads to Unprecedented Response Rate in Patients with Stage IV Pancreatic Cancer

March 2017, Vol 7, No 3 - GI Cancers Symposium

The addition of cisplatin to standard therapy with gemci­tabine and nab-paclitaxel was associated with a median overall survival (OS) that “has not been seen in stage IV pancreatic cancer,” according to Gayle Jameson, MSN, ACNP-BC, Nurse Practitioner Investigator of Clinical Trials, HonorHealth Research Institute, Scottsdale, AZ, who reported the results from a phase 1b single-arm pilot study using the triplet at the 2017 Gastrointestinal Cancers Symposium. [ Read More ]

Glasdegib, a Hedgehog Inhibitor, Nearly Doubles Survival in Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

February 2017, Vol 7, No 2 - ASH 2016 Highlights

Adding the investigational smoothened (SMO) receptor inhibitor glasdegib to low-dose cytarabine (Depo­Cyt) significantly increased overall survival (OS) compared with low-dose cytarabine monotherapy in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) who were ineligible for intensive chemotherapy, according to a phase 2 study presented by Jorge E. Cortes, MD, Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX, at the 2016 American Society of Hematology meeting. [ Read More ]

Venetoclax plus Bortezomib and Dexamethasone Produces High Responses in Relapsed or Refractory Multiple Myeloma

February 2017, Vol 7, No 2 - ASH 2016 Highlights

The addition of venetoclax (Venclexta) to bortezomib (Velcade) and dexamethasone yields high response rates in patients with relapsed or refractory multiple myeloma, especially in patients with disease that is not refractory to bortezomib and who received 1 to 3 previous lines of therapy, according to findings presented by Philippe Moreau, MD, Department of Hematology, Nantes University Hospital, France, at the 2016 American Society of Hematology meeting.

[ Read More ]

Triplet Therapy That Includes Elotuzumab Stops Progression of High-Risk Smoldering Multiple Myeloma

February 2017, Vol 7, No 2 - ASH 2016 Highlights

High response rates with the combination of elotuzumab (Empliciti), lenalidomide (Revlimid), and dexamethasone in the treatment of patients with high-risk smoldering multiple myeloma suggest that early intervention may be worthwhile in this patient population, based on results from a phase 2 study, said Irene M. Ghobrial, MD, Attending Physician, Medical Oncology, Dana-Farber Cancer Institute, Boston, at the 2016 American Society of Hematology meeting. [ Read More ]

Compliance with Fair Market Value Critical to Hospital-Oncologist Alignments – March 2012

March 2012, Vol 2, No 2 - Cancer Center Business Summit

Chicago, IL—Compliance with fair market value is critical for regulatory compliance in valuations of oncologist-hospital alignments, whether these are professional service agreements or comanagement arrangements, according to presenters at the 2011 Cancer Center Business Summit. “Professional service agreements comanagement arrangements [ Read More ]